|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||133.194 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
2-Aminoindane (2-AI) is a research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug. It acts as a selective substrate for NET and DAT.
Synthetic aminoindanes were originally developed in the context of anti-Parkinsonian drugs as a metabolite of rasagiline and as a tool to be used in psychotherapy. Deaths related to their toxic effects have been observed both in the laboratory in animal studies and in clinical encounters. 2-AI is a rigid analogue of amphetamine and partially substitutes for it in rat discrimination tests.
Sweden's public health agency suggested classifying 2-AI as a hazardous substance, on June 24, 2019.
There are a number of derivatives of 2-aminoindane and its positional isomer 1-aminoindane exist, including:
As of October 2015 2-AI is a controlled substance in China.
2-Aminoindane is not scheduled at the federal level in the United States, but may be considered an analog of amphetamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.